DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS TheracosBio has partnered with the Mark Cuban Cost Plus Drug Company to distribute Brenzavvy.
Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor, recently received approval for use as an adjunct to diet and exercise to enhance glycemic control in adult type 2 diabetes patients. This significant stride in the diabetes therapy market emanates from the TheracosBio program and is anticipated to lower treatment cost barriers, thereby expanding utilization.
Key Points:
- Brenzavvy, backed by data from 23 clinical trials involving more than 5,000 adults with type 2 diabetes, is now approved.
- The drug is administered as a 20mg tablet, once daily in the morning.
- Renal function and volume status should be assessed before initiating Brenzavvy treatment; it’s not recommended for patients with an eGFR less than 30mL/min/1.732 and contraindicated in dialysis patients.
Additional Points:
- A 30-day supply of Brenzavvy is priced at $47.85 plus shipping and handling.
Conclusion:
- The launch of Brenzavvy heralds the first phase of TheracosBio’s mission to bring cost-effective novel medications to the US population.
Endocrinology Latest Posts
- What to Know About Ozempic Microdosing
- How to Increase Estrogen Naturally
- Lipid Panels Lie: ‘It’s Time to Rethink the Way We Evaluate CV Risk—Before It’s Too Late’
- Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage
“The commercialization of Brenzavvy marks the first phase of the TheracosBio program to bring cost-effective novel medications to the US population, expanding markets by reducing barriers to greater utilization.”
Albert R. Collinson, PhD
President and CEO
TheracosBio